Loading...

DFTX DEFINIUM THERAPEUTICS INC Expansion Plans 8-K Filing

DFNM

DFTX

DEFINIUM THERAPEUTICS INC

(DFTX)

2026 8-K

Patient Dosing Announced

Financial Results Announced

Investor Update

Financial Results Report

Board Appointment

Name Change Announcement

Financial Results Announcement

Public Offering Announcement

Financial Update

Clinical Trial Results

Financial Statements

Financial Statements

Loan Agreement Amendment

Financial Results

Management Changes

Financial Results

Q2 Financial Results

Public Offering

Sales Agreement

Other Special Situation

Meeting of Shareholders

Offering and Private Placement

Conference Call and Webcast

FDA Breakthrough Designatio...

Earnings Reports

Positive Clinical Trial Res...

Financial Results Announcement

Corporate Presentation Update

Earnings Reports

Annual General Meeting

Analyst Day on MM-120 Progr...

Adjournment of Annual Meeting

Adjournment of Annual Meeting

Conference Presentation

Clinical Trial Enrollment

Financial Results Announcement

Departure of Directors

Positive Data from Phase 2 ...

Financial Results Announcement

External Links:

On May 12, 2026, Definium Therapeutics, Inc. announced that the first patient has been dosed in their Phase 3 study of the DT120 tablet for treating Major Depressive Disorder, marking a significant progress in their clinical trials.

AI Assistant

DEFINIUM THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.